טוען...
Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer
INTRODUCTION: The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that celecoxib, a Cyclooxygenase-2 inhibitor, has antitumor activity in NSCLC and can...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3859308/ https://ncbi.nlm.nih.gov/pubmed/18978565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818b194e |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|